Sangamo Therapeutics (NASDAQ:SGMO) shares traded on 12.43% up secure line and closed at $9.5. The stock exchanged hands 2.15 Million shares versus average trading capacity of 1.71 Million shares. It has a market cap of $754.21 Million.

Wall Street analysts are predicting that Sangamo Therapeutics (NASDAQ:SGMO) will report earnings per share of $-0.19 in their quarterly report. For the current quarter Sangamo Therapeutics (NASDAQ:SGMO) has high EPS estimates of $0.07 in contradiction of low EPS estimates of $-0.29. However a year ago for the same quarter the company has reported $-0.38 EPS. Average estimation for the current quarter has been provided by 6 analysts.

Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. Earnings surprises can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time. Hence, it’s not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Sangamo Therapeutics (NASDAQ:SGMO) reported $-0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.26 by $0.03 with surprise factor of 11.5%.

Sangamo Therapeutics (NASDAQ:SGMO) has average revenue estimates of $5.98 Million, compared to low analyst estimates of $4 Million and high estimates of $10.4 Million for the current quarter. A total number of 5 analysts provided estimations over revenues. For the current year the company’s revenue estimates are $20.29 Million compared to low analyst estimates of $18 Million and high estimates of $22.7 Million according to the prediction of 5 analysts.

Taking a broader look at the analyst consensus, according to 5 analysts Sangamo Therapeutics (NASDAQ:SGMO)’s price will reach at $11.8 during 52 weeks. Its minimum price target estimates has been figured out at $5 while the maximum price target forecast is established at $20.

On the other hand Sangamo Therapeutics (NASDAQ:SGMO) has Relative Strength Index (RSI 14) of 61.76 along with Average True Range (ATR 14) of 0.54. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days) as suggested by J Welles Wilder. In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The average true range (ATR) is a measure of volatility introduced by Welles Wilder.

Consequently Sangamo Therapeutics (NASDAQ:SGMO)’s weekly and monthly volatility is 6.69%, 6.29% respectively.

Sangamo Therapeutics (NASDAQ:SGMO) shares traded on 12.43% up secure line and closed at $9.5. The stock exchanged hands 2.15 Million shares versus average trading capacity of 1.71 Million shares. It has a market cap of $754.21 Million.

Wall Street analysts are predicting that Sangamo Therapeutics (NASDAQ:SGMO) will report earnings per share of $-0.19 in their quarterly report. For the current quarter Sangamo Therapeutics (NASDAQ:SGMO) has high EPS estimates of $0.07 in contradiction of low EPS estimates of $-0.29. However a year ago for the same quarter the company has reported $-0.38 EPS. Average estimation for the current quarter has been provided by 6 analysts.

Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. Earnings surprises can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time. Hence, it’s not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Sangamo Therapeutics (NASDAQ:SGMO) reported $-0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.26 by $0.03 with surprise factor of 11.5%.

Sangamo Therapeutics (NASDAQ:SGMO) has average revenue estimates of $5.98 Million, compared to low analyst estimates of $4 Million and high estimates of $10.4 Million for the current quarter. A total number of 5 analysts provided estimations over revenues. For the current year the company’s revenue estimates are $20.29 Million compared to low analyst estimates of $18 Million and high estimates of $22.7 Million according to the prediction of 5 analysts.

Taking a broader look at the analyst consensus, according to 5 analysts Sangamo Therapeutics (NASDAQ:SGMO)’s price will reach at $11.8 during 52 weeks. Its minimum price target estimates has been figured out at $5 while the maximum price target forecast is established at $20.

On the other hand Sangamo Therapeutics (NASDAQ:SGMO) has Relative Strength Index (RSI 14) of 61.76 along with Average True Range (ATR 14) of 0.54. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days) as suggested by J Welles Wilder. In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The average true range (ATR) is a measure of volatility introduced by Welles Wilder.

Consequently Sangamo Therapeutics (NASDAQ:SGMO)’s weekly and monthly volatility is 6.69%, 6.29% respectively.